Fourpath Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
VCM
VPM
Fourpath Capital Management's PFE Position: Q1 2026 in Review
Fourpath Capital Management increased its Pfizer (PFE) stake by 13% in Q1 2026, buying an estimated $138K and bringing the position to 44,715 shares worth $1.26M. The position accounts for 0.18% of the portfolio, ranked #88.
Fourpath Capital Management first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Fourpath Capital Management held 44,715 shares of Pfizer worth $1.26M as of Q1 2026.
- Fourpath Capital Management bought 5,179 Pfizer shares in Q1 2026, an estimated $138K.
- Pfizer made up 0.18% of Fourpath Capital Management's portfolio in Q1 2026, its #88 holding.
- Fourpath Capital Management first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.